Failure by the marketing authorisation or registration holder to report to the pharmacovigilance database referred to in Article 74 of Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC any suspected adverse reaction, in accordance with Article 76(2) of the same Regulation, shall be punishable by two years’ imprisonment and a fine of €30,000.